Sanofi announced a $1.15 billion acquisition of London-based biotechnology company Vicebio, including potential milestone payments up to $450 million, to expand its respiratory virus vaccine portfolio. Vicebio's lead candidate, VXB-241, a Phase 1 combination vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), will add a non-mRNA vaccine to Sanofi's pipeline. Vicebio’s proprietary molecular clamp technology, developed at the University of Queensland, aims to elicit strong immune responses and simplify vaccine production. The transaction is expected to close in the fourth quarter of 2025, reinforcing Sanofi's position in combination vaccines for respiratory diseases.